1 |
LCB 2183 inhibits tracheal hyperreactivity and pulmonary inflammation in mouse airways. Eur J Pharmacol. 1995 Aug 25;282(1-3):103-9.
|
2 |
LCB 2183 inhibits the inflammation associated with oxazolone-induced contact sensitivity. Int J Immunopharmacol. 1994 Aug;16(8):675-83.
|
3 |
Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
|
4 |
Mechanism of action of MY-1250, an active metabolite of Repirinast, in inhibiting histamine release from rat mast cells. Br J Pharmacol. 1992 Mar;105(3):587-90.
|
5 |
Oxidation of histamine H1 antagonist mequitazine is catalyzed by cytochrome P450 2D6 in human liver microsomes. J Pharmacol Exp Ther. 1998 Feb;284(2):437-42.
|
6 |
Clinical pipeline report, company report or official report of e-Therapeutics.
|
7 |
CA patent application no. 520580, Histamine binding compounds for treatment method for disease conditions mediated by neutrophils.
|
8 |
Clinical pipeline report, company report or official report of Orexo.
|
9 |
Effects of tesmilifene, a substrate of CYP3A and an inhibitor of P-glycoprotein, on the pharmacokinetics of intravenous and oral docetaxel in rats. J Pharm Pharmacol. 2010 Aug;62(8):1084-8.
|
10 |
Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025139)
|
11 |
Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016819)
|
|
|
|
|
|
|